Post by The Lancet Infectious Diseases

📢A booster dose of the yellow fever vaccine given to children in an endemic setting was safe and boosted neutralising antibodies 💡 In a phase 3, open-label trial in The Gambia, Caitlin Pley and colleagues enrolled 610 healthy children in three age cohorts (1-3 years, 4-5 years, and 6-9 years). All children had received a single dose of the yellow fever vaccine between 9 and 12 months of age. Seropositivity increased from 65% (oldest cohort), 67% (middle cohort), and 82% (youngest cohort) pre-booster to 98–99% in all cohorts 28 days post-booster. Fold-changes in neutralising antibody titres were significantly higher in the two older-age groups than in the youngest age group. 🔥In 2014, WHO concluded yellow fever vaccination provides lifelong protection, removing the previous recommendation for a booster every 10 years. However, evidence of waning immunity after the primary dose in children in endemic settings warranted the performance of this trial, the results of which could inform need and optimal timing of yellow fever booster vaccination in children in such settings.   Read the full paper here: https://bit.ly/4v61Txk #YellowFever #Booster #Immunisation #Immunology #PublicHealth #GlobalHealth #ClinicalTrial #Gambia Caitlin Pley, David J Jeffries, Ebrima K Kanteh, Julia Strandmark, PhD, Aru-kumba Baldeh, Mam Nabou Leigh, Peter Ndow, Clarke Ed, Beate Kampmann